Released on = November 6, 2006, 2:18 pm

Press Release Author = Debra Thai

Industry = Biotech

Press Release Summary = The overexpression of the c-erbB-2 (HER-2/neu) gene product,
a 185 kDa transmembrane receptor protein, is associated with cell transformation and
tumorigenesis.

Press Release Body = It shares homology with the epidermal growth factor receptor
and intrinsic tyrosine kinase activity, HER-2/neu gene is amplified and
overexpressed in 25-30% of human breast and ovarian cancers. Overexpression of the
protein, as determined by immunohistochemistry, is associated with poor prognosis
(1,2).

One of the most important mammalian cell cycle checkpoint proteins is the tumor
suppressor protein, p53. In normal, undamaged cells, p53 is rapidly degraded.
However, when cells are treated with DNA damage-inducing agents, there is a
transient accumulation of p53 protein and it is activated as a transcription factor.
In several types of human cancers, p53 is mutated (3,4). Human p53 protein has been
shown to be phosphorylated at several N-terminal and C-terminal sites that affect
site-specific DNA binding and interaction with other cellular and viral proteins in
vitro (5-10). Phosphorylation at serines 6, 9, 15, 20, 33, 37 occur after cells are
exposed either to ionizing radiation or to UV light (11,12). Serines 6 and 15 were
demonstrated to be one of the strongest and earliest phosphorylated sites in
response to DNA damage-induced posttranslational modifications (13, 14).

With a focus on providing targeted solutions for cancer research, AnaSpec, a leading
provider of integrated proteomics solutions, offers a highly specific selection of
c-erbB-2 (HER-2/ neu) and p53 polyclonal antibodies. AnaSpec's collection of p53
antibody products includes both phosphospecific and non-phosphospecific solutions.

Anti-C-erbB-2

Anti-P53 (pSer6), phospho-specific

Anti-P53 (Paired6), non-phospho-specific

Anti-P53 (pSer9), phospho-specific

Anti-P53 (Paired9), non-phospho-specific

Anti-P53 (pSer15), phospho-specific

Anti-P53 (Paired15), non-phospho-specific

For more information on AnaSpec's cancer research antibodies, visit www.anaspec.com

References:
1. Hudson, LG. et al. J. Biol. Chem. 265, 2389 (1990).
2. Reese, DM and DJ. Slamon. Stem Cells 15, 1 (1997).
3. Brown, JM et al (1999) Cancer Res. 59:1391-1399
4. Albrechtsen, N et al (1999) Oncogene 18:7706-7717
5. Wang, L. et al (2001) J. Biol Chem. 276, 43604 (2001).
6. Xirodimas, D et al (2001) Oncogene 20 (36):4972-83
7. Backlund, MG et al (2001) Cancer Res. 61(17): 6577-82
8. Sakaguchi, K et al (2000) J. Biol. Chem. 275:9278-83
9. Banin, S et al (1998) Science 281: 1674-1677
10. Canman, CE et al (1998) Science 281: 1677-1679
11. Burns, TF et al J. cell Physiol. 181: 231-239
12. Oren, M et al (1999) J. Biol. Chem 274:36031-36034
13. Lakin, ND et al (1999) Oncogene 18: 7644-7655
14. Higashimoto, Y et al (2000) J Biol Chem. 275:23199-23203




Web Site = http://www.anaspec.com

Contact Details = 2149 O\'Toole Ave.
San Jose, CA 95131
Tel: 800-452-5530
Fax: 408-452-5059
service@anaspec.com
www.anaspec.com